MedTrace Logo

Clinical Trial of Tolcapone for Cognition in Schizophrenia

NCT00044083 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2018-09-27

Study results available
· View outcomes & findings →

Summary

This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain.

...

Conditions

Interventions

OTHER

Placebo

Placebo: One capsule 3 times a day from Day 1 to Day 7

DRUG

Tolcapone

Tolcapone: One capsule 3 times a day from Day 1 to Day 7

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Jose A Apud, M.D. · National Institute of Mental Health (NIMH)

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044083 on ClinicalTrials.gov